Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

Serono completes enrollment in phase III trial of Serostim

Serono has announced that it has completed enrollment in its second multi-center, phase III trial of Serostim (somatropin [rDNA origin] for injection) in the treatment of HIV-Associated Adipose Redistribution Syndrome (HARS).

24 Jan 2005

Serono announces the availability of Saizen for adult growth hormone deficiency

Serono announced today the availability of Saizen [somatropin (rDNA origin) for injection] for use in the treatment of patients with adult growth hormone deficiency (AGHD), following its FDA approval.

10 Jan 2005

Tercica files for patent infringement

Tercica announced today the filing of a suit for patent infringement in the High Court of Justice (Chancery Division Patents Court) in the United Kingdom against Insmed Incorporated of Glen Allen, Virginia and Avecia Limited of the United Kingdom.

20 Dec 2004

Obesity drug codenamed AOD9604 highly successful in trials

An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.

16 Dec 2004

Successful human trial of obesity drug that mimicks metabolic effects of growth hormone

The AOD9604 molecule is a small orally active peptide modelled on one section of the human growth hormone molecule. Growth hormone naturally occurs in the body and has profound stimulatory effects on fat metabolism, with levels of the hormone typically becoming suppressed in the obese state.

13 Dec 2004

Flu vaccine shortage highlights need to accelerate the approval of affordable generic biopharmaceuticals and vaccines

Following the announcement that the nation is facing a flu vaccine shortage this year, the Generic Pharmaceutical Association (GPhA) renewed its call for the Food and Drug Administration (FDA) and Congress to move forward to accelerate the approval of affordable generic biopharmaceuticals and vaccines.

8 Oct 2004

New biological principle and therapeutic goal for cancer treatment

Pioneering research on leukaemia cells can have identified their vulnerable spot. This new knowledge can now be used to produce more effective medicines.

14 Sep 2004

Study challenges early age intervention with human growth hormone

A new study counters the prevailing belief that children and adolescents who are extra short have social adjustment problems and fewer friends than children of average height, challenging one rationale for intervening at an early age with human growth-hormone treatment.

7 Sep 2004

New guidelines today to diagnose and treat acromegaly

The American Association of Clinical Endocrinologists (AACE) released new guidelines today to diagnose and treat acromegaly, a rare and debilitating endocrine disorder. The guidelines are published in the May/June 2004 issue of AACE's peer-reviewed journal Endocrine Practice.

29 Aug 2004

Ways to economically recover recombinant proteins from transgenic tobacco

The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.

12 Aug 2004

Second case of variant Creutzfeldt-Jakob disease infection that was probably caused by blood transfusion

Research reported in The Lancet this week details the second case of variant Creutzfeldt-Jakob disease (vCJD) infection that was probably caused by blood transfusion. The rogue prion responsible for vCJD was identified at postmortem five years after an elderly person received a blood transfusion from a donor who later developed vCJD.

5 Aug 2004

New precautionary measures against the possible risk of transmission of variant Creutzfeldt Jakob Disease

The UK Department of Health (DOH) has said today that recipients of blood transfusions are to be excluded from donating blood in the future as a further precautionary measure against the possible risk of transmission of variant Creutzfeldt Jakob Disease (vCJD), Health Secretary John Reid announced today.

23 Jul 2004

Natural organohalogens have potent anticancer and antibacterial activity

Human made chemical compounds called organohalogens get loads of attention as they are best known for their often harmful effect on the environment - substances like the CFCs (the ozone-damaging chemicals), dioxin (found in the herbicide Agent Orange), PCBs (industrial fluids) and several pesticides.

22 Jul 2004

Increasing levels of growth hormone may be an effective treatment for HIV lipodystrophy

Increasing the body's production of growth hormone may be an effective treatment for HIV lipodystrophy, a syndrome involving the redistribution of fat and other metabolic changes in those receiving combination drug therapy for HIV infection.

11 Jul 2004

Yo-yo dieting may have a lasting negative impact on immune function

Yo-yo dieting, in which a person repeatedly loses and regains weight, may have a lasting negative impact on immune function, according to new findings by researchers at Fred Hutchinson Cancer Research Center.

1 Jun 2004

Study indicates the number of people in the UK who could be incubating vCJD

The Journal of Pathology recently published a paper entitled Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. The study looked at 12,674 stored appendix and tonsil samples, and found that 3 of them showed evidence of the prion protein associated with variant Creutzfeldt-Jakob Disease (vCJD).

25 May 2004

Launch of Zorbtive for use in the treatment of patients with short bowel syndrome

Serono, Inc., the US affiliate of Serono, announced today the launch of Zorbtive™ [somatropin (rDNA origin) for injection] for use in the treatment of patients with short bowel syndrome.

25 May 2004

No evidence of CJD associated with the Garden State Racetrack

The Department of Health and Senior Services released a report today on an investigation of a suspected cluster of Creutzfeldt-Jakob Disease (CJD) associated with the Garden State Racetrack.

8 May 2004

New hope for advances in treatment methods for AIDS, Alzheimer's and age-related blindness

Pharmaceutical science leaders from the FDA, research institutions and top pharmaceutical companies will gather at the 2004 AAPS National Biotechnology Conference, AAPS' spring annual meeting.

4 May 2004

First drug product for treatment of short bowel syndrome

Short bowel syndrome (SBS) is a rare and potentially life-threatening condition in which the ability of the small intestine to absorb the nutrition a person needs from food is impaired. Short bowel syndrome can occur after surgical removal of part of the intestine, due to trauma or because the intestine is diseased.

4 May 2004